Last $9.62 USD
Change Today +0.28 / 3.00%
Volume 1.0M
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$9.42
Previous Close
$9.34
Day High
$9.65
Day Low
$9.16
52 Week High
01/24/14 - $18.18
52 Week Low
04/28/14 - $6.88
Market Cap
1.2B
Average Volume 10 Days
1.7M
EPS TTM
$-0.70
Shares Outstanding
125.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of pancreatic cancer; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; and Baxter Healthcare Corporation. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

170 Employees
Last Reported Date: 02/28/14
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $314.9K
Chief Scientific Officer and Vice President
Total Annual Compensation: $321.4K
Consultant
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

Halozyme Therapeutics, Inc. announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. The company is currently conducting a Phase 2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE). In October 2014, the company disclosed that the U.S. Food and Drug Administration also granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer. The EMA Orphan Designation is a status assigned to a medicine intended for use against a rare condition (prevalence of the condition in the European Union must not be more than 5 in 10,000) and allows a pharmaceutical company to benefit from incentives offered by the EU to develop a medicine for the treatment, prevention or diagnosis of a disease that is life-threatening or a chronically debilitating rare disease. In addition to a 10-year period of marketing exclusivity in the EU after product approval, Orphan Drug Designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to centralized marketing authorization. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan. Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need.

Halozyme Therapeutics, Inc. Announces License Agreement with Janssen Biotech Inc

Halozyme Therapeutics, Inc. announced that it has entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. (Janssen) for developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE(TM) technology. Under the terms of the agreement, Halozyme will develop and commercialize products for up to five targets combining rHuPH20 with Janssen's proprietary compounds. Halozyme will receive an initial payment of $15 million, and is eligible to receive additional payments upon Janssen's achievement of specified development, regulatory and sales-based milestones, totaling up to $566 million. Halozyme is also entitled to royalty payments based on net sales of products using the ENHANZE technology.

Halozyme Therapeutics, Inc. Announces Presentations of Preclinical Data at San Antonio Breast Cancer Symposium Annual Meeting

Halozyme Therapeutics, Inc. announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) on Dec. 12, 2014. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors. SABCS Poster Presentation Details: Title: Hyaluronan Depletion Sensitizes HAhigh Tumors to Antibody-Dependent Cell-Mediated Cytotoxicity. About 50% of HER2+3 breast cancers and 12% of ovarian cancers accumulate abundant HA in the tumor microenvironment. The accumulation of HA is known to result in decreased access of therapeutics to the tumor. Therefore, HA accumulation may contribute to trastuzumab resistance. When HA is depleted by treatment with PEGPH20 in vitro, HAhigh/HER2+3 cells become much more sensitive to antibody-mediated cellular cytotoxicity. Additionally, HAhigh/HER2+3 human tumors in mice treated with PEGPH20 increased the access of trastuzumab and immune cells to the tumor, resulting in enhanced antitumor activity. These results suggest that co-administration of PEGPH20 could enhance the efficacy of trastuzumab in HAhigh/HER2+3 tumors. Title: Naked Mole Rat HAS2 and Hyaluronan Are Not Tumor Suppressive in Human Tumor Xenografts. Published third-party literature suggests that naked mole rat hyaluronan synthase 2 (nmrHAS2) produces extraordinarily high molecular weight HA, which has tumor suppressive effects. Transfection of the nmrHAS2 gene into human tumor cells did not suppress the growth of human tumors in nude mice and suggests that HA in the naked mole rat may have different functions than in human cancer, where HA accumulation promotes tumor growth.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $9.62 USD +0.28

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $11.84 USD +0.10
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.8x
Price/Book 29.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.